Epidermal growth factor receptor signalling contributes to osteoblastic stromal cell proliferation, osteoclastogenesis and disease progression in giant cell tumour of bone

Histopathology

Volumn 59, Issue 3, 2011, Pages 376-389

  Balla, Peter ^a   Moskovszky, Linda ^a   Sapi, Zoltan ^a   Forsyth, Ramses ^b   Knowles, Helen ^c   Athanasou, Nick A ^d   Szendroi, Miklos ^a   Kopper, Laszlo ^a   Rajnai, Hajnalka ^a   Pinter, Ferenc ^e   Petak, Istvan ^a,e   Benassi, Maria Serena ^f   Picci, Piero ^f   Conti, Amalia ^f   Krenacs, Tibor ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d NUFFIELD ORTHOPAEDIC CENTRE   (United Kingdom)

^e KPS Medical Biotechnology and Healthcare Services Ltd   (Hungary)

^f RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

Author keywords

Epidermal growth factor receptor; GCTB progression; Giant cell tumour of bone; Receptor tyrosine kinases

Indexed keywords

COLONY STIMULATING FACTOR 1; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPITOPE; PHOSPHOTYROSINE; TRANSFORMING GROWTH FACTOR ALPHA;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER TISSUE; CELL PROLIFERATION; CHILD; CONTROLLED STUDY; FEMALE; GENE DOSAGE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING; MALE; MICROARRAY ANALYSIS; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOCLASTOMA; PARACRINE SIGNALING; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENT CANCER; SCHOOL CHILD; SIGNAL TRANSDUCTION; STROMA CELL; TISSUE MICROARRAY; TUMOR GROWTH;

ADOLESCENT; ADULT; AGED; BONE NEOPLASMS; BONE RESORPTION; CELL PROLIFERATION; DISEASE PROGRESSION; FEMALE; GIANT CELL TUMOR OF BONE; HUMANS; MALE; MIDDLE AGED; MUTATION; OSTEOBLASTS; OSTEOCLASTS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; STROMAL CELLS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 80053322539     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2011.03948.x     Document Type: Article

References (48)

1. Robling AG, Castillo AB, Turner CH. Biomechanical and molecular regulation of bone remodeling. Ann. Rev. Biomed. Eng. 2006; 8; 455-498.
2. Knowles HJ, Athanasou NA. Canonical and non-canonical pathways of osteoclast formation. Histol. Histopathol. 2009; 24; 337-346.
3. Teitelbaum SL, Ross FP. Genetic regulation of osteoclast development and function. Nat. Rev. Genet. 2003; 4; 638-649.
4. Zhu J, Jia X, Xiao G, Kang Y, Partridge NC, Qin L. EGF-like ligands stimulate osteoclastogenesis by regulating expression of osteoclast regulatory factors by osteoblasts: implications for osteolytic bone metastases. J. Biol. Chem. 2007; 282; 26656-26664.
5. Szendroi M. Giant-cell tumour of bone. J. Bone Joint Surg. Br. 2004; 86; 5-12.
6. Hubbard SR, Mohammadi M, Schlessinger J. Autoregulatory mechanisms in protein-tyrosine kinases. J. Biol. Chem. 1998; 273; 11987-11990.
7. Blume-Jensen P, Hunter T. Oncogenic kinase signaling. Nature 2001; 411; 355-365.
8. Chien HH, Lin WL, Cho MI. Down-regulation of osteoblastic cell differentiation by epidermal growth factor receptor. Calcif. Tissue Int. 2000; 67; 141-150.
9. Sibilia M, Wagner B, Hoebertz A et al. Mice humanised for the EGF receptor display hypomorphic phenotypes in skin, bone and heart. Development 2003; 130; 4515-4525.
10. Wang K, Yamamoto H, Chin JR, Werb Z, Vu TH. Epidermal growth factor receptor-deficient mice have delayed primary endochondral ossification because of defective osteoclast recruitment. J. Biol. Chem. 2004; 279; 53848-53856.
11. Tamama K, Fan VH, Griffith LG, Blair HC, Wells A. Epidermal growth factor as a candidate for ex vivo expansion of bone marrow-derived mesenchymal stem cells. Stem Cells 2006; 24; 686-695.
12. Fan VH, Tamama K, Au A et al. Tethered epidermal growth factor provides a survival advantage to mesenchymal stem cells. Stem Cells 2007; 25; 1241-1251.
13. De Luca A, Carotenuto A, Rachiglio A et al. The role of the EGFR signaling in tumor microenvironment. J. Cell. Physiol. 2008; 214; 559-567.
14. Kersting C, Gebert C, Agelopoulos K et al. Epidermal growth factor receptor expression in high-grade osteosarcomas is associated with a good clinical outcome. Clin. Cancer Res. 2007; 13; 2998-3005.
15. Wen YH, Koeppen H, Garcia R. Epidermal growth factor receptor in osteosarcoma: expression and mutational analysis. Hum. Pathol. 2007; 38; 1184-1191.
16. Balke M, Schremper L, Gebert C et al. Giant cell tumor of bone; treatment and outcome of 214 cases. J. Cancer Res. Clin. Oncol. 2008; 134; 969-978.
17. Lau YS, Sabokbar A, Gibbons CL, Giele H, Athanasou NA. Phenotypic and molecular studies of giant-cell tumors of bone and soft tissue. Hum. Pathol. 2005; 36; 945-954.
18. Salerno M, Avnet S, Alberghini M, Giunti A, Baldini N. Histogenetic characterization of giant cell tumor of bone. Clin. Orthop. Relat. Res. 2008; 2466; 2081-2091.
19. Roessner A, von Bassewitz DB, Schlake W, Thorwesten G, Grundmann E. Biologic characterization of human bone tumors. III. Giant cell tumor of bone. A combined electron microscopical, histochemical, and autoradiographical study. Pathol. Res. Pract. 1984; 178; 431-440.
20. Moskovszky L, Szuhai K, Krenács T et al. Genomic instability in giant cell tumor of bone. A study of 52 cases using DNA ploidy, relocalization FISH, and array-CGH analysis. Genes Chromosom. Cancer 2009; 48; 468-479.
21. Gorunova L, Vult von Steyern F, Storlazzi CT et al. Cytogenetic analysis of 101 giant cell tumors of bone; nonrandom patterns of telomeric associations and other structural aberrations. Genes Chromosom. Cancer 2009; 48; 583-602.
22. Forsyth RG, De Boeck G, Bekaert S et al. Telomere biology in giant cell tumour of bone. J. Pathol. 2008; 214; 555-563.
23. Gebre-Medhin S, Broberg K, Jonson T et al. Telomeric associations correlate with telomere length reduction and clonal chromosome aberrations in giant cell tumor of bone. Cytogenet. Genome Res. 2009; 124; 121-127.
24. Horvai AE, Kramer MJ, Garcia JJ, O'Donnell RJ. Distribution and prognostic significance of human telomerase reverse transcriptase (hTERT) expression in giant-cell tumor of bone. Mod. Pathol. 2008; 21; 423-430.
25. Masui F, Ushigome S, Fujii K. Giant cell tumor of bone: an immunohistochemical comparative study. Pathol. Int. 1998; 48; 355-361.
26. Gamberi G, Benassi MS, Böhling T et al. Prognostic relevance of C-myc gene expression in giant-cell tumor of bone. J. Orthop. Res. 1998; 16; 1-7.
27. Schoedel KE, Greco MA, Stetler-Stevenson WG et al. Expression of metalloproteinases and tissue inhibitors of metalloproteinases in giant cell tumor of bone: an immunohistochemical study with clinical correlation. Hum. Pathol. 1996; 27; 1144-1148.
28. Ferracini R, Scotlandi K, Cagliero E et al. The expression of Met/hepatocyte growth factor receptor gene in giant cell tumors of bone and other benign musculoskeletal tumors. J. Cell. Physiol. 2000; 184; 191-196.
29. Zheng MH, Xu J, Robbins P et al. Gene expression of vascular endothelial growth factor in giant cell tumors of bone. Hum. Pathol. 2000; 31; 804-812.
30. Kumta SM, Huang L, Cheng YY, Chow LT, Lee KM, Zheng MH. Expression of VEGF and MMP-9 in giant cell tumor of bone and other osteolytic lesions. Life Sci. 2003; 73; 1427-1436.
31. Sanerkin NG. Malignancy, aggressiveness, and recurrence in giant cell tumor of bone. Cancer 1980; 46; 1641-1649.
32. Fornasier VL, Protzner K, Zhang I, Mason L. The prognostic significance of histomorphometry and immunohistochemistry in giant cell tumors of bone. Hum. Pathol. 1996; 27; 754-760.
33. Antal I, Sapi Z, Szendroi M. The prognostic significance of DNA cytophotometry and proliferation index (Ki-67) in giant cell tumors of bone. Orthopade 1999; 23; 315-319.
34. Campanacci M, Baldini N, Boriani S, Sudanese A. Giant-cell tumor of bone. J. Bone Joint Surg. Am. 1987; 69; 106-114.
35. Enneking WF. A system for staging musculoskeletal neoplasms. Clin. Orthop. Relat. Res. 1986; 204; 9-24.
36. Derecskei K, Moldvay J, Bogos K, Timar J. Protocol modifications influence the result of EGF receptor immunodetection by EGFR pharmDx in paraffin-embedded cancer tissues. Pathol. Oncol. Res. 2006; 12; 243-246.
37. Krenacs T, Krenacs L, Raffeld M. Multiple antigen immunostaining procedures. Methods Mol. Biol. 2010; 588; 281-300.
38. Pinter F, Papay J, Almasi A et al. Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry. J. Mol. Diagn. 2008; 10; 160-168.
39. Kudo O, Sabokbar A, Pocock A, Itonaga I, Fujikawa Y, Athanasou NA. Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone 2003; 32; 1-7.
40. Knowles HJ, Athanasou NA. Acute hypoxia and osteoclast activity: a balance between enhanced resorption and increased apoptosis. J. Pathol. 2009; 218; 256-264.
41. Normanno N, De Luca A, Aldinucci D. Gefitinib inhibits the ability of human bone marrow stromal cells to induce osteoclast differentiation: implications for the pathogenesis and treatment of bone metastasis. Endocr. Relat. Cancer 2005; 12; 471-482.
42. Yi T, Lee HL, Cha JH et al. Epidermal growth factor receptor regulates osteoclast differentiation and survival through cross-talking with RANK signaling. J. Cell. Physiol. 2008; 217; 409-422.
43. Valente RC, Nascimento CR, Araujo EG, Rumjanek VM. mCD14 expression in human monocytes is downregulated by ouabain via transactivation of epithelial growth factor receptor and activation of p38 mitogen-activated protein kinase. Neuroimmunomodulation 2009; 16; 228-236.
44. Franovic A, Gunaratnam L, Smith K, Robert I, Patten D, Lee S. Translational up-regulation of the EGFR by tumor hypoxia provides a nonmutational explanation for its overexpression in human cancer. Proc. Natl Acad. Sci. USA 2007; 104; 13092-13097.
45. Rho JK, Choi YJ, Lee JK et al. Gefitinib circumvents hypoxia-induced drug resistance by the modulation of HIF-1alpha. Oncol. Rep. 2009; 21; 801-807.
46. Laderoute KR, Grant TD, Murphy BJ, Sutherland RM. Enhanced epidermal growth factor receptor synthesis in human squamous carcinoma cells exposed to low levels of oxygen. Int. J. Cancer 1992; 52; 428-432.
47. Nishi H, Nishi KH, Johnson AC. Early growth response-1 gene mediates up-regulation of epidermal growth factor receptor expression during hypoxia. Cancer Res. 2002; 62; 827-834.
48. Peng XH, Karna P, Cao Z, Jiang BH, Zhou M, Yang L. Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1alpha signal pathways increases resistance to apoptosis by up-regulating survivin gene expression. J. Biol. Chem. 2006; 281; 25903-25914.